Home/Stocks/DHR
Public stock intelligence

Danaher Corporation with price, financials, news flow, and insider context in one page.

Danaher Corporation is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where DHR sits inside Healthcare and Diagnostics & Research, and the key financial markers that matter before moving into a fuller research workflow.

HealthcareDiagnostics & ResearchNYQUnited States
Live price
$165.34
Session move
-0.55% today
Next earnings
Jul 21, 2026
Market cap
117.01B
Volume
4.47M
52-week range
3% through the 52-week range
Forward P/E
18.18
Revenue growth
3.7%
Dividend yield
96.0%
Price history
Daily closes for DHR, with a quick range selector for public research.
About the company

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Employees
58,000
Beta
0.84
ROE
7.1%
Current ratio
1.87
Visit company website
Research framing

This page is structured for research context, not a trade call. It gives you a clean read on where DHR sits in its range, what the last few quarters look like, and which headlines are shaping attention.

For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.

Quarterly financials
QuarterRevenueNet incomeFree cash flow
Q1 20265.95B1.03B1.09B
Q4 20256.84B1.2B1.75B
Q3 20256.05B908M1.37B
Q2 20255.94B555M1.09B
Insider activity
SPOON ALAN G
Director
May 1, 2026
Transaction
Conversion of Exercise of derivative security at price 71.88 per share.
Value
237.06K
SPOON ALAN G
Director
May 1, 2026
Transaction
Sale at price 174.67 per share.
Value
237.21K
BLAIR RAINER M
Chief Executive Officer
Feb 27, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
GUTIERREZ-RAMOS JOSE-CARLOS
Officer
Feb 27, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
GRAY ROBERT BRADLEY
Officer
Feb 27, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
LEIKEN JONATHAN B
Officer
Feb 27, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
Why this page ranks

A public stock page should answer the first research questions before asking for a signup.

This DHR page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.

The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.